标题
SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
作者
关键词
-
出版物
Cardiovascular Diabetology
Volume 20, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-04-29
DOI
10.1186/s12933-021-01276-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- SGLT2 inhibitors and the autonomic nervous system in diabetes: A promising challenge to better understand multiple target improvement
- (2021) Vincenza Spallone et al. DIABETES & METABOLISM
- Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults
- (2021) Elisabetta Patorno et al. DIABETES CARE
- Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
- (2020) Shih-Chieh Shao et al. Cardiovascular Diabetology
- SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
- (2020) Milton Packer DIABETES CARE
- Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
- (2020) Valentina Spigoni et al. Cardiovascular Diabetology
- Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of five randomized controlled trials
- (2020) Satoshi Miyashita et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis
- (2020) James Heyward et al. PLoS One
- Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor
- (2020) Hsin-Fu Lee et al. Cardiovascular Diabetology
- Class effects of SGLT2 inhibitors on cardiorenal outcomes
- (2019) Aaron Y. Kluger et al. Cardiovascular Diabetology
- Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment
- (2018) Ichiro Horie et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus
- (2018) H. Sims et al. DIABETIC MEDICINE
- Does lower limb amputation concern all SGLT2 inhibitors?
- (2018) André J. Scheen Nature Reviews Endocrinology
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus
- (2016) Sachie Hirose et al. INTERNAL MEDICINE
- Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
- (2014) Lawrence A. Leiter et al. DIABETES CARE
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence
- (2012) A. R. Meloni et al. DIABETES OBESITY & METABOLISM
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started